CD68 and nonpapillary renal cell carcinoma: Furthermore, ccRCC patients with high CD163+ TAMs showed a trend of advanced UICC-stage (OR 4.55, 95% CI 1.65–12.57, I2 = 0.0%, p = 0.084) while CD68+ TAMs did not (OR: 2.80, 95% CI 0.88–8.96, I2 = 69.8%, p = 0.036) (Figure 3E).